Success Metrics

Clinical Success Rate
62.5%

Based on 5 completed trials

Completion Rate
63%(5/8)
Active Trials
1(11%)
Results Posted
80%(4 trials)
Terminated
3(33%)

Phase Distribution

Ph phase_4
2
22%
Ph not_applicable
1
11%
Ph phase_2
2
22%
Ph early_phase_1
2
22%
Ph phase_1
2
22%

Phase Distribution

4

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
2(22.2%)
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 4Post-market surveillance
2(22.2%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(5)
Terminated(3)

Detailed Status

Completed5
Terminated3
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
62.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (22.2%)
Phase 12 (22.2%)
Phase 22 (22.2%)
Phase 42 (22.2%)
N/A1 (11.1%)

Trials by Status

terminated333%
completed556%
active_not_recruiting111%

Recent Activity

1 active trials
Showing 5 of 9
completedearly_phase_1

CBD-Microglia PET Study

NCT04398719
active_not_recruitingearly_phase_1

Neuroinflammation Imaging in AD

NCT04274998
completedphase_4

Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation

NCT04230174
completedphase_2

Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies

NCT02702102
completedphase_2

Imaging Inflammation in Alzheimer's Disease

NCT02831283
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04398719Early Phase 1

CBD-Microglia PET Study

Completed
NCT04274998Early Phase 1

Neuroinflammation Imaging in AD

Active Not Recruiting
NCT04230174Phase 4

Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation

Completed
NCT02702102Phase 2

Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies

Completed
NCT02831283Phase 2

Imaging Inflammation in Alzheimer's Disease

Completed
NCT04490096Phase 1

Multimodal Imaging Outcome Measures for ALS (Image ALS)

Terminated
NCT03231397Phase 4

Predictors of AAA Expansion and/or Rupture

Terminated
NCT00459693Not Applicable

PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)

Terminated
NCT00432900Phase 1

Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis

Completed

All 9 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
9